Lesogaberan - Misplaced Pages

Lesogaberan
Names


Preferred IUPAC name phosphinic acid
Other names AZD-3355
Identifiers
CAS Number	344413-67-8=
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL448343
ChemSpider	23254384
ECHA InfoCard	100.133.162
IUPHAR/BPS	7705
PubChem CID	9833984
UNII	4D6Q6HGC7Z
CompTox Dashboard (EPA)	DTXSID20188011
InChI InChI=1S/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1Key: LJNUIEQATDYXJH-GSVOUGTGSA-N InChI=1/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1Key: LJNUIEQATDYXJH-GSVOUGTGBQ
SMILES O=(O)C(F)CN
Properties
Chemical formula	C₃H₉FNO₂P
Molar mass	141.082 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references

Chemical compound

Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABA_B receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.

References

AstraZeneca. "AZD3355". Retrieved 30 December 2011.
Bredenoord, Albert J. (2009). "Lesogaberan, a GABA_B agonist for the potential treatment of gastroesophageal reflux disease". IDrugs. 12 (9): 576–584. PMID 19697277.
Alstermark; Amin, K; Dinn, SR; et al. (2008). "Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors". Journal of Medicinal Chemistry. 51 (14): 4315–4320. doi:10.1021/jm701425k. PMID 18578471.
Brian E. Lacy; Robert Chehade; Michael D. Crowell (2010). "Lesogaberan". Drugs of the Future. 35 (12): 987–992. doi:10.1358/dof.2010.035.012.1540661. S2CID 258021903.

v t e Drugs for peptic ulcer and GERD/GORD (A02B)
H₂ antagonists ("-tidine")	Cimetidine Famotidine Lafutidine Lavoltidine (loxtidine) Niperotidine Nizatidine Ranitidine Roxatidine
Prostaglandins (E)/ analogues ("-prost-")	Misoprostol Enprostil
Proton-pump inhibitors ("-prazole")	Anaprazole Azeloprazole Dexlansoprazole Dexrabeprazole Esomeprazole Ilaprazole Lansoprazole Omeprazole Pantoprazole Picoprazole Rabeprazole Tenatoprazole Timoprazole
Potassium-competitive acid blockers ("-prazan")	Fexuprazan Linaprazan Revaprazan Soraprazan Tegoprazan Vonoprazan Zastaprazan
Others	Aceglutamide aluminum Acetoxolone Alginic acid Arbaclofen placarbil Bismuth subcitrate Carbenoxolone Cetraxate Gefarnate Irsogladine Lesogaberan Pirenzepine Proglumide Rebamipide Sucralfate Sulglicotide Telenzepine Teprenone Troxipide Zinc L-carnosine Zolimidine
Combinations	Bismuth subcitrate/metronidazole/tetracycline Omeprazole/amoxicillin/rifabutin Vonoprazan/amoxicillin Vonoprazan/amoxicillin/clarithromycin
See also: Helicobacter pylori* eradication protocols*
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

GABA_ATooltip γ-Aminobutyric acid A receptor

GABA_A-ρTooltip γ-Aminobutyric acid A-rho receptor

GABA_BTooltip γ-Aminobutyric acid B receptor

See also: Receptor/signaling modulators; GABA_A receptor positive modulators; GABA metabolism/transport modulators

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.